SCOPE 1: A phase II/III trial of chemoradiotherapy in esophageal cancer plus or minus cetuximab.
Thomas Crosby
No relevant relationships to disclose
Chris Hurt
No relevant relationships to disclose
Stephen Falk
No relevant relationships to disclose
Simon Gollins
No relevant relationships to disclose
Somnath Mukherjee
No relevant relationships to disclose
John Staffurth
No relevant relationships to disclose
Ruby Ray
No relevant relationships to disclose
John A. Bridgewater
No relevant relationships to disclose
Ian Geh
No relevant relationships to disclose
David Cunningham
Research Funding - AstraZeneca; Merck; Roche
Tim Maughan
Research Funding - Merck Serono
Gareth Griffiths
No relevant relationships to disclose